Loading...

TxCell

DB:0TC
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0TC
DB
€66M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

TxCell S.A., a biotechnology company, develops cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity, and transplantation. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
0TC Share Price and Events
7 Day Returns
0.2%
DB:0TC
1.8%
DE Biotechs
1.6%
DE Market
1 Year Returns
76.7%
DB:0TC
-4.5%
DE Biotechs
-13.7%
DE Market
0TC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TxCell (0TC) 0.2% 1% 6.7% 76.7% -63.6% -
DE Biotechs 1.8% 1.1% -12.4% -4.5% 42.3% 1.6%
DE Market 1.6% 0.8% -8.5% -13.7% -0.2% 12.1%
1 Year Return vs Industry and Market
  • 0TC outperformed the Biotechs industry which returned -4.5% over the past year.
  • 0TC outperformed the Market in Germany which returned -13.7% over the past year.
Price Volatility
0TC
Industry
5yr Volatility vs Market

Value

 Is TxCell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TxCell. This is due to cash flow or dividend data being unavailable. The share price is €2.56.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TxCell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TxCell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0TC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.53
DB:0TC Share Price ** DB (2018-11-26) in EUR €2.56
Europe Biotechs Industry PE Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 29.75x
Germany Market PE Ratio Median Figure of 413 Publicly-Listed Companies 17.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TxCell.

DB:0TC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:0TC Share Price ÷ EPS (both in EUR)

= 2.56 ÷ -0.53

-4.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TxCell is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TxCell is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TxCell's expected growth come at a high price?
Raw Data
DB:0TC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-41.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.21x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TxCell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TxCell's assets?
Raw Data
DB:0TC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.01
DB:0TC Share Price * DB (2018-11-26) in EUR €2.56
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.59x
Germany Market PB Ratio Median Figure of 555 Publicly-Listed Companies 1.84x
DB:0TC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:0TC Share Price ÷ Book Value per Share (both in EUR)

= 2.56 ÷ 0.01

390.66x

* Primary Listing of TxCell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TxCell is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess TxCell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TxCell has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TxCell expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-41.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TxCell expected to grow at an attractive rate?
  • Unable to compare TxCell's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare TxCell's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • TxCell's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0TC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0TC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -41.8%
DB:0TC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 71.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0TC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0TC Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31
2020-12-31 13 -30 -31 1
2019-12-31 3 -10 -11 1
2018-12-31 3 -11 -12 1
DB:0TC Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 2 -10 -12
2018-03-31 2 -10 -12
2017-12-31 2 -10 -11
2017-09-30 3 -10 -11
2017-06-30 3 -9 -12
2017-03-31 3 -10 -13
2016-12-31 3 -10 -14
2016-09-30 3 -10 -13
2016-06-30 3 -10 -13
2016-03-31 4 -10 -12
2015-12-31 4 -10 -11
2015-09-30 4 -11 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TxCell is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • TxCell's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0TC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from TxCell Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0TC Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2020-12-31
2019-12-31
2018-12-31
DB:0TC Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.53
2018-03-31 -0.53
2017-12-31 -0.52
2017-09-30 -0.62
2017-06-30 -0.76
2017-03-31 -0.89
2016-12-31 -1.04
2016-09-30 -1.01
2016-06-30 -0.99
2016-03-31 -0.96
2015-12-31 -0.93
2015-09-30 -0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TxCell will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess TxCell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TxCell has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TxCell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TxCell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TxCell does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TxCell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TxCell's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TxCell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TxCell Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0TC Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 1.99 -12.23 4.26 8.62
2018-03-31 2.11 -11.57 4.44 8.37
2017-12-31 2.23 -10.91 4.63 8.11
2017-09-30 2.53 -11.34 4.53 8.56
2017-06-30 2.82 -11.77 4.16 9.30
2017-03-31 2.88 -12.67 4.52 10.03
2016-12-31 2.95 -13.57 4.89 10.75
2016-09-30 3.22 -13.12 4.86 10.75
2016-06-30 3.48 -12.66 4.83 10.75
2016-03-31 3.76 -11.98 4.39 10.80
2015-12-31 4.03 -11.30 3.94 10.84
2015-09-30 4.12 -10.23 3.78 10.33
2015-06-30 4.21 -9.17 3.61 9.82
2015-03-31 3.81 -8.72 3.74 8.83
2014-12-31 3.42 -8.27 3.86 7.84
2014-09-30 2.70 -7.86 3.48 7.07
2014-06-30 1.99 -7.45 3.09 6.31
2014-03-31 1.88 -6.45 2.32 5.99
2013-12-31 1.77 -5.45 1.55 5.67
2012-12-31 1.12 -5.52 1.56 3.80
2011-12-31 1.26 -3.84 1.45 3.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TxCell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TxCell has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TxCell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TxCell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TxCell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TxCell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TxCell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TxCell's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • TxCell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TxCell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TxCell Company Filings, last reported 5 months ago.

DB:0TC Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 0.15 9.87 4.40
2018-03-31 0.15 9.87 4.40
2017-12-31 5.17 3.36 4.91
2017-09-30 5.17 3.36 4.91
2017-06-30 7.83 4.88 8.68
2017-03-31 7.83 4.88 8.68
2016-12-31 1.19 5.29 3.48
2016-09-30 1.19 5.29 3.48
2016-06-30 5.16 1.65 3.20
2016-03-31 5.16 1.65 3.20
2015-12-31 11.59 1.64 9.21
2015-09-30 11.59 1.64 9.21
2015-06-30 9.49 1.63 7.72
2015-03-31 9.49 1.63 7.72
2014-12-31 14.71 1.63 13.92
2014-09-30 14.71 1.63 13.92
2014-06-30 17.72 0.00 17.36
2014-03-31 17.72 0.00 17.36
2013-12-31 2.20 0.00 0.68
2012-12-31 4.75 0.01 3.85
2011-12-31 -0.10 1.82 0.53
  • TxCell's level of debt (6494.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 6494.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TxCell has less than a year of cash runway based on current free cash flow.
  • TxCell has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.2% each year.
X
Financial health checks
We assess TxCell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TxCell has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TxCell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TxCell dividends.
If you bought €2,000 of TxCell shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TxCell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TxCell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0TC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0TC Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TxCell has not reported any payouts.
  • Unable to verify if TxCell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TxCell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TxCell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TxCell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TxCell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TxCell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TxCell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • TxCell has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the TxCell management team in years:

2.8
Average Tenure
54.5
Average Age
  • The tenure for the TxCell management team is about average.
Management Team

François Meyer

TITLE
Executive Chairman & Head of Research
COMPENSATION
€341K
AGE
69
TENURE
2 yrs

Raphael Flipo

TITLE
Senior VP & CFO
TENURE
5.5 yrs

Caroline Courme

TITLE
IR & Communication Director

Arnaud Foussat

TITLE
Senior VP of Corporate Development and Head of External Collaborations & Alliance Management
TENURE
2 yrs

Tim Schmidt

TITLE
Chief Translational Research Officer
TENURE
0.8 yrs

Virginie Neveu

TITLE
Manufacturing Director

Pierre Tiberghien

TITLE
Scientific Director

Liliane Guilmin

TITLE
Vice President of Project Management
AGE
53
TENURE
3 yrs

Pierre Heimendinger

TITLE
Vice President of Process Development
AGE
56
TENURE
3 yrs

Maud Bouvier

TITLE
Vice President of Business Development
AGE
40
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the TxCell board of directors in years:

3.6
Average Tenure
63.5
Average Age
  • The tenure for the TxCell board of directors is about average.
Board of Directors

François Meyer

TITLE
Executive Chairman & Head of Research
COMPENSATION
€341K
AGE
69
TENURE
5 yrs

David Solomon

TITLE
Additional Independent Director
COMPENSATION
€46K
AGE
58
TENURE
3.6 yrs

Zelig Eshhar

TITLE
Chairman of Scientific Advisory Board
TENURE
2.6 yrs

Bernard Malissen

TITLE
Member of Scientific Advisory Board

Pierre Desreumaux

TITLE
Member of Medical Advisory Board

Bernard Daugeras

TITLE
Director
AGE
75

Thibaut Roulon

TITLE
Director

Laurent Arthaud

TITLE
Board Observer
AGE
55

Marie-Laure Garrigues

TITLE
Director

William Sandborn

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • TxCell insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Nov 18 Buy Sangamo Therapeutics, Inc. Company 23. Nov 18 23. Nov 18 166,690 €2.58 €430,060
23. Nov 18 Buy Sangamo Therapeutics, Inc. Company 22. Nov 18 22. Nov 18 173,501 €2.58 €447,633
22. Nov 18 Buy Sangamo Therapeutics, Inc. Company 21. Nov 18 21. Nov 18 85,224 €2.58 €219,878
21. Nov 18 Buy Sangamo Therapeutics, Inc. Company 20. Nov 18 20. Nov 18 186,663 €2.58 €481,591
20. Nov 18 Buy Sangamo Therapeutics, Inc. Company 19. Nov 18 19. Nov 18 1,453,834 €2.58 €3,750,892
20. Nov 18 Buy Sangamo Therapeutics, Inc. Company 16. Nov 18 16. Nov 18 1,453,834 €2.58 €3,750,892
20. Nov 18 Sell Oddo Bhf Asset Management SAS Company 19. Nov 18 19. Nov 18 -1,150,000 €2.58 €-2,967,000
19. Nov 18 Buy Sangamo Therapeutics, Inc. Company 16. Nov 18 16. Nov 18 107,594 €2.58 €277,593
16. Nov 18 Buy Sangamo Therapeutics, Inc. Company 15. Nov 18 15. Nov 18 537,657 €2.58 €1,387,155
15. Nov 18 Buy Sangamo Therapeutics, Inc. Company 14. Nov 18 14. Nov 18 141,340 €2.58 €364,657
14. Nov 18 Buy Sangamo Therapeutics, Inc. Company 13. Nov 18 13. Nov 18 365,500 €2.58 €942,990
13. Nov 18 Buy Sangamo Therapeutics, Inc. Company 12. Nov 18 12. Nov 18 143,790 €2.58 €370,978
12. Nov 18 Buy Sangamo Therapeutics, Inc. Company 09. Nov 18 09. Nov 18 105,594 €2.58 €272,433
09. Nov 18 Buy Sangamo Therapeutics, Inc. Company 08. Nov 18 08. Nov 18 215,132 €2.58 €555,041
08. Nov 18 Buy Sangamo Therapeutics, Inc. Company 07. Nov 18 07. Nov 18 66,496 €2.58 €171,560
07. Nov 18 Buy Sangamo Therapeutics, Inc. Company 06. Nov 18 06. Nov 18 132,541 €2.58 €341,956
06. Nov 18 Buy Sangamo Therapeutics, Inc. Company 05. Nov 18 05. Nov 18 251,471 €2.58 €648,795
05. Nov 18 Buy Sangamo Therapeutics, Inc. Company 02. Nov 18 02. Nov 18 69,134 €2.58 €178,366
02. Nov 18 Buy Sangamo Therapeutics, Inc. Company 01. Nov 18 01. Nov 18 2,787,875 €2.58 €7,192,718
09. Oct 18 Buy Sangamo Therapeutics, Inc. Company 08. Oct 18 08. Oct 18 260,776 €2.58 €672,802
08. Oct 18 Buy Sangamo Therapeutics, Inc. Company 05. Oct 18 05. Oct 18 1,445,735 €2.58 €3,729,996
05. Oct 18 Sell Claire Berdou Individual 04. Oct 18 04. Oct 18 -251,808 €2.58 €-649,665
05. Oct 18 Buy Sangamo Therapeutics, Inc. Company 04. Oct 18 04. Oct 18 1,737,079 €2.58 €4,479,102
21. Sep 18 Buy Claire Berdou Individual 20. Sep 18 20. Sep 18 28,285 €2.51 €70,995
24. Jul 18 Buy Oddo Bhf Asset Management SAS Company 23. Jul 18 23. Jul 18 1,150,000 €2.33 €2,679,500
X
Management checks
We assess TxCell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TxCell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

TxCell S.A., a biotechnology company, develops cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity, and transplantation. Its cellular therapy products are composed of Tregs with a chimeric antigen receptor (CAR). The company’s product candidates include TX200, a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation. It is also involved in the development of CAR-Treg-based cellular immunotherapies for bullous pemphigoid, a rare potentially fatal autoimmune disease, as well as for the treatment of multiple sclerosis; and Ovasave for refractory Crohn's disease. The company has strategic research and development collaboration agreements with the Lübeck Institute of Experimental Dermatology, University of British Columbia, and Center for Research in Transplantation and Immunology. TxCell S.A. is headquartered in Valbonne, France. As of October 1, 2018, TxCell S.A. operates as a subsidiary of Sangamo Therapeutics, Inc.

Details
Name: TxCell S.A.
0TC
Exchange: DB
Founded:
€65,663,329
25,450,903
Website: http://www.txcell.com
Address: TxCell S.A.
Allée de la Nertière,
Les Cardoulines HT1,
Valbonne,
Provence-Alpes-Côte d'Azur, 06560,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB 0TC Ordinary Shares Deutsche Boerse AG DE EUR 14. Apr 2014
LSE 0QTN Ordinary Shares London Stock Exchange GB EUR 14. Apr 2014
BATS-CHIXE TXCLP Ordinary Shares BATS 'Chi-X Europe' GB EUR 14. Apr 2014
Number of employees
Current staff
Staff numbers
46
TxCell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/30 19:40
End of day share price update: 2018/11/26 00:00
Last estimates confirmation: 2018/11/28
Last earnings filing: 2018/09/19
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.